Скачать или смотреть Podcast: Developing Liraglutide: A GLP-1 Peptide for Type 2 Diabetes Management | Veeda Group

Liraglutide has demonstrated remarkable efficacy in managing Type 2 Diabetes Mellitus, and Veeda Group has been at the forefront of supporting the development of complex drugs like Liraglutide for more than a decade.

Till date, Veeda Group has conducted 15 glucose clamp studies across a variety of insulin products, including Insulin Glargine, Insulin Aspart, and Wosulin. In addition to our work with Liraglutide, our team has substantial experience with Semaglutide, another leading GLP-1 receptor agonist.

In this episode, Dr. Jatin Vadhvana, Head of the Clinical Research Department, discusses Veeda Group’s expertise in complex drugs like liraglutide. He explains the key steps we take to conduct successful studies for these intricate drugs, solidifying our position as a preferred partner in Type 2 Diabetes drug development.

Tune in to the podcast now!

Partners in creating a healthier tomorrow.

To know more, visit us at ➦ https://veedalifesciences.com/ or write to us at [email protected].

If you like this video, do not forget to thumbs up, comment, and share this video.

Get notified of our new videos, click subscribe, and press the bell icon.    / @veedacr  

➦ Get social with us:
◉ Facebook:   / veedacr  
◉ Instagram:   / veedacr  
◉ Twitter:   / veedacr  
◉ LinkedIn:   / veedacr  
◉ Youtube:    / @veedacr  

#Veeda #VeedaCR #VeedaGroup #Podcast #Peptide #Diabetes #DiabetesManagement #Liraglutide #Type2Diabetes #DiabetesManagement #ComplexDrugDevelopment #GlucoseClampStudies #InsulinProducts #InsulinGlargine #InsulinAspart #Wosulin #Semaglutide #GLP1ReceptorAgonists #ClinicalResearch #DiabetesDrugDevelopment #DrJatinVadhvana #ClinicalResearchExpertise #PreferredPartner #Type2DiabetesTreatment #DrugDevelopment #PharmaceuticalStudies #DiabetesCare